Compare Stocks

→ Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXI Avenue Therapeutics	$0.09 -29.8%	$0.15	$0.09 ▼ $1.25	$4.17M	-0.24	4.54 million shs	12.28 million shs
BLPH Bellerophon Therapeutics	$0.05	$0.05	$0.03 ▼ $11.15	$662K	0.67	61,081 shs	47,040 shs
BNTC Benitec Biopharma	$6.72 -2.0%	$4.99	$1.86 ▼ $9.01	$17.41M	1.03	67,559 shs	66,355 shs
EYEG AB Corporate Bond ETF	$34.72 -0.3%	$1.90	$1.44 ▼ $8.18	$24.31M	0.13	935,975 shs	5,000 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXI Avenue Therapeutics	+3.00%	+1.82%	-11.38%	-4.29%	-86.25%
BLPH Bellerophon Therapeutics	+14.68%	+7.52%	+6.55%	+1.03%	-99.32%
BNTC Benitec Biopharma	+2.08%	+43.51%	+38.59%	+140.70%	+93.63%
EYEG AB Corporate Bond ETF	+0.23%	+0.77%	-2.36%	-1.72%	+1,685.38%

Thousands of investors use this no cost solution | Do you? (Ad)

In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.

Simply tap here now to subscribe and start getting "Insider Financial Advantage"

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATXI Avenue Therapeutics	1.2196 of 5 stars	0.0	5.0	0.0	4.6	2.8	0.0	0.0
BLPH Bellerophon Therapeutics	2.1088 of 5 stars	3.0	0.0	0.0	4.8	3.2	0.0	0.6
BNTC Benitec Biopharma	1.5492 of 5 stars	3.5	3.0	0.0	0.0	2.3	0.8	0.0
EYEG AB Corporate Bond ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXI Avenue Therapeutics	3.00	Buy	N/A	N/A
BLPH Bellerophon Therapeutics	2.00	Hold	$2.00	3,596.86% Upside
BNTC Benitec Biopharma	3.00	Buy	$16.00	138.10% Upside
EYEG AB Corporate Bond ETF	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ATXI, EYEG, BNTC, and BLPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/22/2024	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $16.00
2/15/2024	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$8.00 ➝ $10.00
1/24/2024	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$6.00 ➝ $8.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	$0.03 per share	N/A
BLPH Bellerophon Therapeutics	$5.64M	0.12	N/A	N/A	$0.27 per share	0.20
BNTC Benitec Biopharma	$80K	217.56	N/A	N/A	$0.12 per share	56.00
EYEG AB Corporate Bond ETF	$10K	2,430.54	N/A	N/A	$1.26 per share	27.56

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXI Avenue Therapeutics	-$10.38M	-$1.27	N/A	∞	N/A	N/A	N/A	-335.11%	5/10/2024 (Estimated)
BLPH Bellerophon Therapeutics	-$19.83M	-$0.84	N/A	∞	N/A	N/A	-187.35%	-104.97%	5/13/2024 (Estimated)
BNTC Benitec Biopharma	-$19.56M	N/A	0.00	∞	N/A	N/A	-204.34%	-142.81%	5/20/2024 (Estimated)
EYEG AB Corporate Bond ETF	-$8.09M	-$1.68	N/A	N/A	N/A	N/A	-104.96%	-60.03%	N/A

Latest ATXI, EYEG, BNTC, and BLPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/18/2024	Q4 2023	ATXI Avenue Therapeutics	N/A	$0.56	+$0.56	$0.56	N/A	N/A
2/13/2024	Q2 2024	BNTC Benitec Biopharma	N/A	-$2.64	-$2.64	-$2.64	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	N/A
BLPH Bellerophon Therapeutics	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
EYEG AB Corporate Bond ETF	N/A	N/A	N/A	N/A	N/A

Latest ATXI, EYEG, BNTC, and BLPH Dividends

Announcement	Company	Period	Amount	Ex-Dividend Date	Record Date	Payable Date
3/28/2024	EYEG AB Corporate Bond ETF	Monthly	$0.1572	4/1/2024	4/2/2024	4/5/2024
2/29/2024	EYEG AB Corporate Bond ETF	Monthly	$0.1486	3/1/2024	3/4/2024	3/7/2024
1/31/2024	EYEG AB Corporate Bond ETF	Monthly	$0.1476	2/1/2024	2/2/2024	2/7/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXI Avenue Therapeutics	N/A	1.55	1.55
BLPH Bellerophon Therapeutics	N/A	3.96	3.96
BNTC Benitec Biopharma	0.01	3.62	3.62
EYEG AB Corporate Bond ETF	0.01	3.07	3.07

Ownership

Institutional Ownership

Company	Institutional Ownership
ATXI Avenue Therapeutics	17.34%
BLPH Bellerophon Therapeutics	10.61%
BNTC Benitec Biopharma	52.19%
EYEG AB Corporate Bond ETF	64.16%

Insider Ownership

Company	Insider Ownership
ATXI Avenue Therapeutics	1.80%
BLPH Bellerophon Therapeutics	5.20%
BNTC Benitec Biopharma	4.30%
EYEG AB Corporate Bond ETF	58.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXI Avenue Therapeutics	3	44.26 million	43.46 million	Not Optionable
BLPH Bellerophon Therapeutics	18	12.23 million	11.60 million	No Data
BNTC Benitec Biopharma	18	2.59 million	2.48 million	No Data
EYEG AB Corporate Bond ETF	14	700,000	5.28 million	Not Optionable

ATXI, EYEG, BNTC, and BLPH Headlines

Source	Headline
	BlackRock Set To Slice Corporate Bond ETFs By Sector br.advfn.com - April 22 at 3:05 PM
	Invesco International Corporate Bond ETF declares monthly distribution of $0.0549 msn.com - April 22 at 3:05 PM
	AB Core Bond ETF (EYEG) finance.yahoo.com - April 5 at 5:48 PM
	iShares ESG Aware USD Corporate Bond ETF declares monthly distribution of $0.0781 msn.com - April 1 at 4:11 PM
	BHG Financial Completes First Consumer-Only ABS Transaction, Closes Over $273M in ABS Notes markets.businessinsider.com - March 26 at 9:47 AM
	Invesco BulletShares 2029 Corporate Bond ETF declares monthly distribution of $0.0619 msn.com - March 19 at 7:42 AM
	AMC Entertainment Tops The List Of High-Yielding Corporate Bonds — A Look At Yields As Bond Appetites Grow msn.com - March 18 at 3:48 PM
	Compare with VictoryShares Corporate Bond ETF (UCRD) msn.com - February 25 at 1:31 PM
	Invesco BulletShares 2024 Corporate Bond ETF declares monthly distribution of $0.0544 msn.com - February 20 at 7:43 AM
	Invesco BulletShares 2024 Corporate Bond ETF declares monthly distribution of $0.0521 msn.com - January 22 at 3:16 PM
	Invesco BulletShares 2027 Corporate Bond ETF declares monthly distribution of $0.0683 msn.com - December 18 at 2:17 PM
	US Corporate Bond Issuance Seen Increasing After Yields Slide msn.com - December 18 at 7:46 AM
	iShares ESG Aware 1-5 Year USD Corporate Bond ETF declares monthly distribution of $0.0654 msn.com - December 16 at 6:37 PM
	TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors finance.yahoo.com - November 30 at 8:37 AM
	Kiora Pharmaceuticals (KPRX) Receives a Buy from Maxim Group markets.businessinsider.com - September 15 at 3:15 PM
	Earum Pharmaceuticals share price livemint.com - September 12 at 3:19 AM
	H.C. Wainwright Sticks to Their Buy Rating for Kiora Pharmaceuticals (KPRX) markets.businessinsider.com - August 24 at 6:49 AM
	SUNPHARMA.NS - Sun Pharmaceutical Industries Limited finance.yahoo.com - July 28 at 8:22 PM
	Ocular Drug Delivery System Market sales will total US$ 27.82 Billion by 2031 \| Says Future Market Insights pharmiweb.com - May 16 at 10:52 PM
	S-1: KIORA PHARMACEUTICALS INC marketwatch.com - May 6 at 9:38 AM
	Maxim Group Sticks to Their Buy Rating for Kiora Pharmaceuticals (KPRX) markets.businessinsider.com - April 29 at 3:37 PM
	Ocular Inflammation Treatment Market Facts and Figures By 2030 marketwatch.com - April 18 at 11:07 PM
	Dry Eye Medication Market Average Price by Manufacturers marketwatch.com - March 30 at 12:36 AM
	Uveitis Treatment Market Growth and Forecast till 2028 marketwatch.com - March 23 at 7:35 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Avenue Therapeutics

NASDAQ:ATXI

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Bellerophon Therapeutics

NASDAQ:BLPH

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Benitec Biopharma

NASDAQ:BNTC

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

AB Corporate Bond ETF

NASDAQ:EYEG

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial